Global Metastatic Colorectal Cancer Market By Metastasizing Site (Lungs, Liver, Brain, Lymph Nodes, Others); By Treatment Type (Surgery, Radiation Therapy, Chemo Therapy , Targeted Therapy and Immunotherapy, Image Guided Therapy, Others); By End-User (Healthcare Facilities, Specialized Cancer Centers, Research Centers, Others); By Application (Kids, Adults); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Through the growth of human civilization, diseases have plagued the life lives of individuals. However, rapid advancement in medical technology is helping in saving countless lives, and enhancing the life expectancy of humans. Infact, studies show that the human life expectancy could reach 130 years by the end of 21st century. One disease that is causing widespread concern amongst researchers is cancer. Cancer is a disease which causes uncontrollable growth of cells in the human body. The cells become old, and die out, and new cells are formed based on the needs of the body. The breakdown of this process leads to cancer, as the cells start multiplying in an uncontrolled and haphazard manner. This leads to the growth of lumps of cell tissues called tumours. The process of these tumours invade other body parts to form new tumours, which is referred to as metastasis. Colorectal cancer originates in the colon or rectum. When this cancer spreads to other parts of the body such as lungs, heart, brain, etc., the cancer is called metastatic colorectal cancer. The diagnosis of colorectal cancer is complicated, and late diagnosis can prove detrimental for individuals. By 2035, around 2.4 million cases of colorectal cancer are expected to be reported each year globally. The rising demand for the faster detection and treatment of metastatic colorectal cancer, coupled with the rise in awareness about metastasis of colorectal cancer, is leading to the growth of the global metastatic colorectal cancer market.
COVID-19 Impact:
2020 saw the growth of COVID-19 infections globally, and numerous individuals were massively affected as a result of the same. The pandemic has created additional burden on the healthcare sector, and the total number of cases of individuals visiting hospitals for general check-ups saw a fall during this period. The detection of colorectal cancer became increasingly difficult as a result of the same. However, larger emphasis was laid on the detection of cancer cases, as individuals with cancer were at high risk of being drastically affected by the virus as the disease progressed. The pandemic has created additional challenges for the diagnosis and therapeutics of colorectal cancer, but the global metastatic colorectal cancer market is expected to see rapid growth in the coming years due to the rise in investment in cancer research during the pandemic.
In terms of revenue, the global metastatic colorectal cancer market is growing at a CAGR of 9.81% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Metastatic Colorectal Cancer Market Revenue & Forecast, (US$ Million), 2021 – 2029
Application Outlook:
Adults accounted for the highest revenue share in the global metastatic colorectal cancer market in 2020. Studies show that around 746,000 men and 614,000 women were affected by metastatic colorectal cancer annually. The cancer is rare in youngsters, and generally affects individuals above the age of 60. For adults who have been diagnosed with colorectal cancer in the initial five years, the survival rate is as high as 93%. Companies are increasingly working on products that can enhance the life expectancy of individuals affected by metastatic colorectal cancer, and the detection of this cancer is expected to become easier in the coming years due to the advancement in imaging technology.
Region Outlook:
North America accounted for the highest market share in the global metastatic colorectal cancer cases in 2020, as far as the regional revenue is concerned. The presence of prominent market participants such as Amgen, Mirati, etc., coupled with advanced detection techniques in healthcare facilities in the U.S and Canada is a major reason for the higher revenue share of North America in the global metastatic colorectal cancer market. Furthermore, the region is also seeing a rise in public funding for metastatic colorectal cancer research. Colorectal Cancer Alliance, for instance, has proposed an additional funding of US$ 1.1 million towards the support of individual scientists for obtaining research grants in metastatic colorectal cancer. The alliance has provided funding of around US$ 3 million since 2016 for the development of cutting edge technologies that can help in saving the lives of individuals affected by colorectal cancer. These factors are enabling North America to amount for the highest revenue share in the global market.
Competitive Landscape
The report provides both, qualitative and quantitative research of the global metastatic colorectal cancer market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of key players operating in the global metastatic colorectal cancer market are:
- Amgen Inc.
- Arcus Biosciences, Inc.
- Array BioPharma Inc
- CARDIFF ONCOLOGY
- Celyad Oncology SA
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd
- Elevar Therapeutics
- F. Hoffmann-La Roche Ltd.
- G1 Therapeutics, Inc.
- Genentech USA, Inc.
- Immunovative Therapies, Ltd.
- Merck KGaA
- Mirati Therapeutics, Inc.
- Novartis AG
- Scandion Oncology A/S
- Shanghai Henlius Biotech, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Suzhou Zelgen Biopharmaceuticals Co., Ltd.
- Symphogen
- The Menarini Group
- Treos Bio Limited
- Other Market Participants
Global Metastatic Colorectal Cancer Market
By Metastasizing Site
- Lungs
- Liver
- Brain
- Lymph Nodes
- Others
By Treatment Type
- Surgery
- Radiation Therapy
- Chemo Therapy
- Targeted Therapy and Immunotherapy
- Image Guided Therapy
- Others
By Application
- Kids
- Adults
By End-User
- Healthcare Facilities
- Specialized Cancer Centers
- Research Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Metastatic Colorectal Cancer Market
6.
Market
Synopsis: Metastatic Colorectal Cancer
Market
7.
Metastatic
Colorectal Cancer Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Metastatic Colorectal Cancer Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Metastatic Colorectal Cancer Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Metastatic Colorectal
Cancer Market
8.
Global
Metastatic Colorectal Cancer Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global Metastatic Colorectal Cancer Market
Revenue (US$ Mn)
8.2. Global Metastatic Colorectal Cancer Market
Revenue (US$ Mn) and Forecasts, By Metastasizing Site
8.2.1. Lungs
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market
Forecast, 2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Liver
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Brain
8.2.3.1.
Definition
8.2.3.2.
Market Estimation
and Penetration, 2015 - 2020
8.2.3.3.
Market
Forecast, 2021 - 2029
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.2.4. Lymph Nodes
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.4.3.
Market
Forecast, 2021 - 2029
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2020
8.2.4.5.1.2. Market Forecast, 2021 - 2029
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2020
8.2.4.5.2.2. Market Forecast, 2021 - 2029
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2020
8.2.4.5.3.2. Market Forecast, 2021 - 2029
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2020
8.2.4.5.4.2. Market Forecast, 2021 - 2029
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2020
8.2.4.5.5.2. Market Forecast, 2021 - 2029
8.2.5. Others
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.5.3.
Market
Forecast, 2021 - 2029
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2020
8.2.5.5.1.2. Market Forecast, 2021 - 2029
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2020
8.2.5.5.2.2. Market Forecast, 2021 - 2029
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2020
8.2.5.5.3.2. Market Forecast, 2021 - 2029
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2020
8.2.5.5.4.2. Market Forecast, 2021 - 2029
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2020
8.2.5.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Metastasizing Site
9.
Global
Metastatic Colorectal Cancer Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Metastatic Colorectal Cancer Market
Revenue (US$ Mn) and Forecasts, By Treatment Type
9.2.1. Surgery
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2. Radiation Therapy
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3. Chemo Therapy
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.3.3.
Market
Forecast, 2021 - 2029
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.2.4. Targeted Therapy and Immunotherapy
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.4.3.
Market
Forecast, 2021 - 2029
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2020
9.2.4.5.1.2. Market Forecast, 2021 - 2029
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2020
9.2.4.5.2.2. Market Forecast, 2021 - 2029
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2020
9.2.4.5.3.2. Market Forecast, 2021 - 2029
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2020
9.2.4.5.4.2. Market Forecast, 2021 - 2029
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2020
9.2.4.5.5.2. Market Forecast, 2021 - 2029
9.2.5. Image Guided Therapy
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.5.3.
Market
Forecast, 2021 - 2029
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2020
9.2.5.5.1.2. Market Forecast, 2021 - 2029
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2020
9.2.5.5.2.2. Market Forecast, 2021 - 2029
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2020
9.2.5.5.3.2. Market Forecast, 2021 - 2029
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2020
9.2.5.5.4.2. Market Forecast, 2021 - 2029
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2020
9.2.5.5.5.2. Market Forecast, 2021 - 2029
9.2.6. Others
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.6.3.
Market
Forecast, 2021 - 2029
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2020
9.2.6.5.1.2. Market Forecast, 2021 - 2029
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2020
9.2.6.5.2.2. Market Forecast, 2021 - 2029
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2020
9.2.6.5.3.2. Market Forecast, 2021 - 2029
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2020
9.2.6.5.4.2. Market Forecast, 2021 - 2029
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2020
9.2.6.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Treatment Type
10. Global Metastatic Colorectal Cancer Market
Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Metastatic Colorectal Cancer Market
Revenue (US$ Mn) and Forecasts, By Application
10.2.1. Kids
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
10.2.1.3.
Market
Forecast, 2021 - 2029
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Adults
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
10.2.2.3.
Market
Forecast, 2021 - 2029
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Application
11. Global Metastatic Colorectal Cancer Market
Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global Metastatic Colorectal Cancer Market
Revenue (US$ Mn) and Forecasts, By End-User
11.2.1. Healthcare Facilities
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
11.2.1.3.
Market
Forecast, 2021 - 2029
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2020
11.2.1.5.1.2. Market Forecast, 2021 - 2029
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2020
11.2.1.5.2.2. Market Forecast, 2021 - 2029
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2020
11.2.1.5.3.2. Market Forecast, 2021 - 2029
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2020
11.2.1.5.4.2. Market Forecast, 2021 - 2029
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2020
11.2.1.5.5.2. Market Forecast, 2021 - 2029
11.2.2. Specialized Cancer Centers
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
11.2.2.3.
Market
Forecast, 2021 - 2029
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2020
11.2.2.5.1.2. Market Forecast, 2021 - 2029
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2020
11.2.2.5.2.2. Market Forecast, 2021 - 2029
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2020
11.2.2.5.3.2. Market Forecast, 2021 - 2029
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2020
11.2.2.5.4.2. Market Forecast, 2021 - 2029
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2020
11.2.2.5.5.2. Market Forecast, 2021 - 2029
11.2.3. Research Centers
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
11.2.3.3.
Market
Forecast, 2021 - 2029
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2020
11.2.3.5.1.2. Market Forecast, 2021 - 2029
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2020
11.2.3.5.2.2. Market Forecast, 2021 - 2029
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2020
11.2.3.5.3.2. Market Forecast, 2021 - 2029
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2020
11.2.3.5.4.2. Market Forecast, 2021 - 2029
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2020
11.2.3.5.5.2. Market Forecast, 2021 - 2029
11.2.4. Others
11.2.4.1.
Definition
11.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
11.2.4.3.
Market
Forecast, 2021 - 2029
11.2.4.4.
Compound
Annual Growth Rate (CAGR)
11.2.4.5.
Regional
Bifurcation
11.2.4.5.1.
North
America
11.2.4.5.1.1. Market Estimation, 2015 - 2020
11.2.4.5.1.2. Market Forecast, 2021 - 2029
11.2.4.5.2.
Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2020
11.2.4.5.2.2. Market Forecast, 2021 - 2029
11.2.4.5.3.
Asia
Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2020
11.2.4.5.3.2. Market Forecast, 2021 - 2029
11.2.4.5.4.
Middle
East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2020
11.2.4.5.4.2. Market Forecast, 2021 - 2029
11.2.4.5.5.
Latin
America
11.2.4.5.5.1. Market Estimation, 2015 - 2020
11.2.4.5.5.2. Market Forecast, 2021 - 2029
11.3. Key Segment for Channeling Investments
11.3.1. By End-User
12. North America Metastatic Colorectal Cancer
Market Analysis and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North America Metastatic Colorectal Cancer
Market Revenue (US$ Mn)
12.2. North America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Metastasizing Site
12.2.1. Lungs
12.2.2. Liver
12.2.3. Brain
12.2.4. Lymph Nodes
12.2.5. Others
12.3. North America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Treatment Type
12.3.1. Surgery
12.3.2. Radiation Therapy
12.3.3. Chemo Therapy
12.3.4. Targeted Therapy and Immunotherapy
12.3.5. Image Guided Therapy
12.3.6. Others
12.4. North America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Application
12.4.1. Kids
12.4.2. Adults
12.5. North America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.1. Healthcare Facilities
12.5.2. Specialized Cancer Centers
12.5.3. Research Centers
12.5.4. Others
12.6. North America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
12.6.1.1.1.
Lungs
12.6.1.1.2.
Liver
12.6.1.1.3.
Brain
12.6.1.1.4.
Lymph
Nodes
12.6.1.1.5.
Others
12.6.1.2.
U.S
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
12.6.1.2.1.
Surgery
12.6.1.2.2.
Radiation
Therapy
12.6.1.2.3.
Chemo
Therapy
12.6.1.2.4.
Targeted
Therapy and Immunotherapy
12.6.1.2.5.
Image
Guided Therapy
12.6.1.2.6.
Others
12.6.1.3.
U.S
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.1.3.1.
Kids
12.6.1.3.2.
Adults
12.6.1.4.
U.S
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
12.6.1.4.1.
Healthcare
Facilities
12.6.1.4.2.
Specialized
Cancer Centers
12.6.1.4.3.
Research
Centers
12.6.1.4.4.
Others
12.6.2. Canada
12.6.2.1.
Canada
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
12.6.2.1.1.
Lungs
12.6.2.1.2.
Liver
12.6.2.1.3.
Brain
12.6.2.1.4.
Lymph
Nodes
12.6.2.1.5.
Others
12.6.2.2.
Canada
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
12.6.2.2.1.
Surgery
12.6.2.2.2.
Radiation
Therapy
12.6.2.2.3.
Chemo
Therapy
12.6.2.2.4.
Targeted
Therapy and Immunotherapy
12.6.2.2.5.
Image
Guided Therapy
12.6.2.2.6.
Others
12.6.2.3.
Canada
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.2.3.1.
Kids
12.6.2.3.2.
Adults
12.6.2.4.
Canada
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
12.6.2.4.1.
Healthcare
Facilities
12.6.2.4.2.
Specialized
Cancer Centers
12.6.2.4.3.
Research
Centers
12.6.2.4.4.
Others
12.6.3. Mexico
12.6.3.1.
Mexico
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
12.6.3.1.1.
Lungs
12.6.3.1.2.
Liver
12.6.3.1.3.
Brain
12.6.3.1.4.
Lymph
Nodes
12.6.3.1.5.
Others
12.6.3.2.
Mexico
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
12.6.3.2.1.
Surgery
12.6.3.2.2.
Radiation
Therapy
12.6.3.2.3.
Chemo
Therapy
12.6.3.2.4.
Targeted
Therapy and Immunotherapy
12.6.3.2.5.
Image
Guided Therapy
12.6.3.2.6.
Others
12.6.3.3.
Mexico
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.3.3.1.
Kids
12.6.3.3.2.
Adults
12.6.3.4.
Mexico
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
12.6.3.4.1.
Healthcare
Facilities
12.6.3.4.2.
Specialized
Cancer Centers
12.6.3.4.3.
Research
Centers
12.6.3.4.4.
Others
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By Metastasizing Site
12.6.4.1.1.
Lungs
12.6.4.1.2.
Liver
12.6.4.1.3.
Brain
12.6.4.1.4.
Lymph
Nodes
12.6.4.1.5.
Others
12.6.4.2.
Rest of
North America Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
12.6.4.2.1.
Surgery
12.6.4.2.2.
Radiation
Therapy
12.6.4.2.3.
Chemo
Therapy
12.6.4.2.4.
Targeted
Therapy and Immunotherapy
12.6.4.2.5.
Image
Guided Therapy
12.6.4.2.6.
Others
12.6.4.3.
Rest of
North America Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts,
By Application
12.6.4.3.1.
Kids
12.6.4.3.2.
Adults
12.6.4.4.
Rest of
North America Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By End-User
12.6.4.4.1.
Healthcare
Facilities
12.6.4.4.2.
Specialized
Cancer Centers
12.6.4.4.3.
Research
Centers
12.6.4.4.4.
Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Metastasizing Site
12.7.3. By Treatment Type
12.7.4. By Application
12.7.5. By End-User
13. Europe Metastatic Colorectal Cancer Market
Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Europe Metastatic Colorectal Cancer Market
Revenue (US$ Mn)
13.2. Europe Metastatic Colorectal Cancer Market
Revenue (US$ Mn) and Forecasts, By Metastasizing Site
13.2.1. Lungs
13.2.2. Liver
13.2.3. Brain
13.2.4. Lymph Nodes
13.2.5. Others
13.3. Europe Metastatic Colorectal Cancer Market
Revenue (US$ Mn) and Forecasts, By Treatment Type
13.3.1. Surgery
13.3.2. Radiation Therapy
13.3.3. Chemo Therapy
13.3.4. Targeted Therapy and Immunotherapy
13.3.5. Image Guided Therapy
13.3.6. Others
13.4. Europe Metastatic Colorectal Cancer Market
Revenue (US$ Mn) and Forecasts, By Application
13.4.1. Kids
13.4.2. Adults
13.5. Europe Metastatic Colorectal Cancer Market
Revenue (US$ Mn) and Forecasts, By End-User
13.5.1. Healthcare Facilities
13.5.2. Specialized Cancer Centers
13.5.3. Research Centers
13.5.4. Others
13.6. Europe Metastatic Colorectal Cancer Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1.
France
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
13.6.1.1.1.
Lungs
13.6.1.1.2.
Liver
13.6.1.1.3.
Brain
13.6.1.1.4.
Lymph
Nodes
13.6.1.1.5.
Others
13.6.1.2.
France
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.6.1.2.1.
Surgery
13.6.1.2.2.
Radiation
Therapy
13.6.1.2.3.
Chemo
Therapy
13.6.1.2.4.
Targeted
Therapy and Immunotherapy
13.6.1.2.5.
Image
Guided Therapy
13.6.1.2.6.
Others
13.6.1.3.
France
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.1.3.1.
Kids
13.6.1.3.2.
Adults
13.6.1.4.
France
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
13.6.1.4.1.
Healthcare
Facilities
13.6.1.4.2.
Specialized
Cancer Centers
13.6.1.4.3.
Research
Centers
13.6.1.4.4.
Others
13.6.2. The UK
13.6.2.1.
The UK
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
13.6.2.1.1.
Lungs
13.6.2.1.2.
Liver
13.6.2.1.3.
Brain
13.6.2.1.4.
Lymph
Nodes
13.6.2.1.5.
Others
13.6.2.2.
The UK
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.6.2.2.1.
Surgery
13.6.2.2.2.
Radiation
Therapy
13.6.2.2.3.
Chemo
Therapy
13.6.2.2.4.
Targeted
Therapy and Immunotherapy
13.6.2.2.5.
Image
Guided Therapy
13.6.2.2.6.
Others
13.6.2.3.
The UK
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.2.3.1.
Kids
13.6.2.3.2.
Adults
13.6.2.4.
The UK
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
13.6.2.4.1.
Healthcare
Facilities
13.6.2.4.2.
Specialized
Cancer Centers
13.6.2.4.3.
Research
Centers
13.6.2.4.4.
Others
13.6.3. Spain
13.6.3.1.
Spain
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
13.6.3.1.1.
Lungs
13.6.3.1.2.
Liver
13.6.3.1.3.
Brain
13.6.3.1.4.
Lymph
Nodes
13.6.3.1.5.
Others
13.6.3.2.
Spain
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.6.3.2.1.
Surgery
13.6.3.2.2.
Radiation
Therapy
13.6.3.2.3.
Chemo
Therapy
13.6.3.2.4.
Targeted
Therapy and Immunotherapy
13.6.3.2.5.
Image
Guided Therapy
13.6.3.2.6.
Others
13.6.3.3.
Spain
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.3.3.1.
Kids
13.6.3.3.2.
Adults
13.6.3.4.
Spain Metastatic
Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
13.6.3.4.1.
Healthcare
Facilities
13.6.3.4.2.
Specialized
Cancer Centers
13.6.3.4.3.
Research
Centers
13.6.3.4.4.
Others
13.6.4. Germany
13.6.4.1.
Germany
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
13.6.4.1.1.
Lungs
13.6.4.1.2.
Liver
13.6.4.1.3.
Brain
13.6.4.1.4.
Lymph
Nodes
13.6.4.1.5.
Others
13.6.4.2.
Germany
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.6.4.2.1.
Surgery
13.6.4.2.2.
Radiation
Therapy
13.6.4.2.3.
Chemo
Therapy
13.6.4.2.4.
Targeted
Therapy and Immunotherapy
13.6.4.2.5.
Image
Guided Therapy
13.6.4.2.6.
Others
13.6.4.3.
Germany
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.4.3.1.
Kids
13.6.4.3.2.
Adults
13.6.4.4.
Germany
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
13.6.4.4.1.
Healthcare
Facilities
13.6.4.4.2.
Specialized
Cancer Centers
13.6.4.4.3.
Research
Centers
13.6.4.4.4.
Others
13.6.5. Italy
13.6.5.1.
Italy
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
13.6.5.1.1.
Lungs
13.6.5.1.2.
Liver
13.6.5.1.3.
Brain
13.6.5.1.4.
Lymph
Nodes
13.6.5.1.5.
Others
13.6.5.2.
Italy
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.6.5.2.1.
Surgery
13.6.5.2.2.
Radiation
Therapy
13.6.5.2.3.
Chemo
Therapy
13.6.5.2.4.
Targeted
Therapy and Immunotherapy
13.6.5.2.5.
Image
Guided Therapy
13.6.5.2.6.
Others
13.6.5.3.
Italy
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.5.3.1.
Kids
13.6.5.3.2.
Adults
13.6.5.4.
Italy
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
13.6.5.4.1.
Healthcare
Facilities
13.6.5.4.2.
Specialized
Cancer Centers
13.6.5.4.3.
Research
Centers
13.6.5.4.4.
Others
13.6.6. Nordic Countries
13.6.6.1.
Nordic
Countries Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts,
By Metastasizing Site
13.6.6.1.1.
Lungs
13.6.6.1.2.
Liver
13.6.6.1.3.
Brain
13.6.6.1.4.
Lymph
Nodes
13.6.6.1.5.
Others
13.6.6.2.
Nordic
Countries Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
13.6.6.2.1.
Surgery
13.6.6.2.2.
Radiation
Therapy
13.6.6.2.3.
Chemo
Therapy
13.6.6.2.4.
Targeted
Therapy and Immunotherapy
13.6.6.2.5.
Image
Guided Therapy
13.6.6.2.6.
Others
13.6.6.3.
Nordic
Countries Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts,
By Application
13.6.6.3.1.
Kids
13.6.6.3.2.
Adults
13.6.6.4.
Nordic
Countries Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts,
By End-User
13.6.6.4.1.
Healthcare
Facilities
13.6.6.4.2.
Specialized
Cancer Centers
13.6.6.4.3.
Research
Centers
13.6.6.4.4.
Others
13.6.6.5.
Nordic
Countries Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts,
By Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
13.6.7.1.1.
Lungs
13.6.7.1.2.
Liver
13.6.7.1.3.
Brain
13.6.7.1.4.
Lymph
Nodes
13.6.7.1.5.
Others
13.6.7.2.
Benelux
Union Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.6.7.2.1.
Surgery
13.6.7.2.2.
Radiation
Therapy
13.6.7.2.3.
Chemo
Therapy
13.6.7.2.4.
Targeted
Therapy and Immunotherapy
13.6.7.2.5.
Image
Guided Therapy
13.6.7.2.6.
Others
13.6.7.3.
Benelux
Union Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.7.3.1.
Kids
13.6.7.3.2.
Adults
13.6.7.4.
Benelux
Union Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
End-User
13.6.7.4.1.
Healthcare
Facilities
13.6.7.4.2.
Specialized
Cancer Centers
13.6.7.4.3.
Research
Centers
13.6.7.4.4.
Others
13.6.7.5.
Benelux
Union Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
13.6.8.1.1.
Lungs
13.6.8.1.2.
Liver
13.6.8.1.3.
Brain
13.6.8.1.4.
Lymph
Nodes
13.6.8.1.5.
Others
13.6.8.2.
Rest of
Europe Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
13.6.8.2.1.
Surgery
13.6.8.2.2.
Radiation
Therapy
13.6.8.2.3.
Chemo
Therapy
13.6.8.2.4.
Targeted
Therapy and Immunotherapy
13.6.8.2.5.
Image
Guided Therapy
13.6.8.2.6.
Others
13.6.8.3.
Rest of
Europe Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.8.3.1.
Kids
13.6.8.3.2.
Adults
13.6.8.4.
Rest of
Europe Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
End-User
13.6.8.4.1.
Healthcare
Facilities
13.6.8.4.2.
Specialized
Cancer Centers
13.6.8.4.3.
Research
Centers
13.6.8.4.4.
Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Metastasizing Site
13.7.3. By Treatment Type
13.7.4. By Application
13.7.5. By End-User
14. Asia Pacific Metastatic Colorectal Cancer
Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia Pacific Metastatic Colorectal Cancer
Market Revenue (US$ Mn)
14.2. Asia Pacific Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Metastasizing Site
14.2.1. Lungs
14.2.2. Liver
14.2.3. Brain
14.2.4. Lymph Nodes
14.2.5. Others
14.3. Asia Pacific Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Treatment Type
14.3.1. Surgery
14.3.2. Radiation Therapy
14.3.3. Chemo Therapy
14.3.4. Targeted Therapy and Immunotherapy
14.3.5. Image Guided Therapy
14.3.6. Others
14.4. Asia Pacific Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Application
14.4.1. Kids
14.4.2. Adults
14.5. Asia Pacific Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.1. Healthcare Facilities
14.5.2. Specialized Cancer Centers
14.5.3. Research Centers
14.5.4. Others
14.6. Asia Pacific Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By Metastasizing
Site
14.6.1.1.1.
Lungs
14.6.1.1.2.
Liver
14.6.1.1.3.
Brain
14.6.1.1.4.
Lymph
Nodes
14.6.1.1.5.
Others
14.6.1.2.
China
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
14.6.1.2.1.
Surgery
14.6.1.2.2.
Radiation
Therapy
14.6.1.2.3.
Chemo
Therapy
14.6.1.2.4.
Targeted
Therapy and Immunotherapy
14.6.1.2.5.
Image
Guided Therapy
14.6.1.2.6.
Others
14.6.1.3.
China
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.1.3.1.
Kids
14.6.1.3.2.
Adults
14.6.1.4.
China
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
14.6.1.4.1.
Healthcare
Facilities
14.6.1.4.2.
Specialized
Cancer Centers
14.6.1.4.3.
Research
Centers
14.6.1.4.4.
Others
14.6.2. Japan
14.6.2.1.
Japan
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
14.6.2.1.1.
Lungs
14.6.2.1.2.
Liver
14.6.2.1.3.
Brain
14.6.2.1.4.
Lymph
Nodes
14.6.2.1.5.
Others
14.6.2.2.
Japan
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
14.6.2.2.1.
Surgery
14.6.2.2.2.
Radiation
Therapy
14.6.2.2.3.
Chemo
Therapy
14.6.2.2.4.
Targeted
Therapy and Immunotherapy
14.6.2.2.5.
Image
Guided Therapy
14.6.2.2.6.
Others
14.6.2.3.
Japan
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.2.3.1.
Kids
14.6.2.3.2.
Adults
14.6.2.4.
Japan
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
14.6.2.4.1.
Healthcare
Facilities
14.6.2.4.2.
Specialized
Cancer Centers
14.6.2.4.3.
Research
Centers
14.6.2.4.4.
Others
14.6.3. India
14.6.3.1.
India
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
14.6.3.1.1.
Lungs
14.6.3.1.2.
Liver
14.6.3.1.3.
Brain
14.6.3.1.4.
Lymph
Nodes
14.6.3.1.5.
Others
14.6.3.2.
India
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
14.6.3.2.1.
Surgery
14.6.3.2.2.
Radiation
Therapy
14.6.3.2.3.
Chemo
Therapy
14.6.3.2.4.
Targeted
Therapy and Immunotherapy
14.6.3.2.5.
Image
Guided Therapy
14.6.3.2.6.
Others
14.6.3.3.
India
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.3.3.1.
Kids
14.6.3.3.2.
Adults
14.6.3.4.
India
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
14.6.3.4.1.
Healthcare
Facilities
14.6.3.4.2.
Specialized
Cancer Centers
14.6.3.4.3.
Research
Centers
14.6.3.4.4.
Others
14.6.4. New Zealand
14.6.4.1.
New
Zealand Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
14.6.4.1.1.
Lungs
14.6.4.1.2.
Liver
14.6.4.1.3.
Brain
14.6.4.1.4.
Lymph
Nodes
14.6.4.1.5.
Others
14.6.4.2.
New
Zealand Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
14.6.4.2.1.
Surgery
14.6.4.2.2.
Radiation
Therapy
14.6.4.2.3.
Chemo
Therapy
14.6.4.2.4.
Targeted
Therapy and Immunotherapy
14.6.4.2.5.
Image
Guided Therapy
14.6.4.2.6.
Others
14.6.4.3.
New
Zealand Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.4.3.1.
Kids
14.6.4.3.2.
Adults
14.6.4.4.
New
Zealand Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.4.4.1.
Healthcare
Facilities
14.6.4.4.2.
Specialized
Cancer Centers
14.6.4.4.3.
Research
Centers
14.6.4.4.4.
Others
14.6.5. Australia
14.6.5.1.
Australia
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
14.6.5.1.1.
Lungs
14.6.5.1.2.
Liver
14.6.5.1.3.
Brain
14.6.5.1.4.
Lymph
Nodes
14.6.5.1.5.
Others
14.6.5.2.
Australia
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
14.6.5.2.1.
Surgery
14.6.5.2.2.
Radiation
Therapy
14.6.5.2.3.
Chemo
Therapy
14.6.5.2.4.
Targeted
Therapy and Immunotherapy
14.6.5.2.5.
Image
Guided Therapy
14.6.5.2.6.
Others
14.6.5.3.
Australia
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.5.3.1.
Kids
14.6.5.3.2.
Adults
14.6.5.4.
Australia
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
14.6.5.4.1.
Healthcare
Facilities
14.6.5.4.2.
Specialized
Cancer Centers
14.6.5.4.3.
Research
Centers
14.6.5.4.4.
Others
14.6.6. South Korea
14.6.6.1.
South
Korea Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
14.6.6.1.1.
Lungs
14.6.6.1.2.
Liver
14.6.6.1.3.
Brain
14.6.6.1.4.
Lymph
Nodes
14.6.6.1.5.
Others
14.6.6.2.
South
Korea Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
14.6.6.2.1.
Surgery
14.6.6.2.2.
Radiation
Therapy
14.6.6.2.3.
Chemo
Therapy
14.6.6.2.4.
Targeted
Therapy and Immunotherapy
14.6.6.2.5.
Image
Guided Therapy
14.6.6.2.6.
Others
14.6.6.3.
South
Korea Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.6.3.1.
Kids
14.6.6.3.2.
Adults
14.6.6.4.
South
Korea Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.6.4.1.
Healthcare
Facilities
14.6.6.4.2.
Specialized
Cancer Centers
14.6.6.4.3.
Research
Centers
14.6.6.4.4.
Others
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
14.6.7.1.1.
Lungs
14.6.7.1.2.
Liver
14.6.7.1.3.
Brain
14.6.7.1.4.
Lymph
Nodes
14.6.7.1.5.
Others
14.6.7.2.
Southeast
Asia Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
14.6.7.2.1.
Surgery
14.6.7.2.2.
Radiation
Therapy
14.6.7.2.3.
Chemo
Therapy
14.6.7.2.4.
Targeted
Therapy and Immunotherapy
14.6.7.2.5.
Image
Guided Therapy
14.6.7.2.6.
Others
14.6.7.3.
Southeast
Asia Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.7.3.1.
Kids
14.6.7.3.2.
Adults
14.6.7.4.
Southeast
Asia Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.7.4.1.
Healthcare
Facilities
14.6.7.4.2.
Specialized
Cancer Centers
14.6.7.4.3.
Research
Centers
14.6.7.4.4.
Others
14.6.7.5.
Southeast
Asia Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By Metastasizing Site
14.6.8.1.1.
Lungs
14.6.8.1.2.
Liver
14.6.8.1.3.
Brain
14.6.8.1.4.
Lymph
Nodes
14.6.8.1.5.
Others
14.6.8.2.
Rest of
Asia Pacific Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.6.8.2.1.
Surgery
14.6.8.2.2.
Radiation
Therapy
14.6.8.2.3.
Chemo
Therapy
14.6.8.2.4.
Targeted
Therapy and Immunotherapy
14.6.8.2.5.
Image
Guided Therapy
14.6.8.2.6.
Others
14.6.8.3.
Rest of
Asia Pacific Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.8.3.1.
Kids
14.6.8.3.2.
Adults
14.6.8.4.
Rest of
Asia Pacific Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.8.4.1.
Healthcare
Facilities
14.6.8.4.2.
Specialized
Cancer Centers
14.6.8.4.3.
Research
Centers
14.6.8.4.4.
Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Metastasizing Site
14.7.3. By Treatment Type
14.7.4. By Application
14.7.5. By End-User
15. Middle East and Africa Metastatic Colorectal
Cancer Market Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle East and Africa Metastatic Colorectal
Cancer Market Revenue (US$ Mn)
15.2. Middle East and Africa Metastatic Colorectal
Cancer Market Revenue (US$ Mn) and Forecasts, By Metastasizing Site
15.2.1. Lungs
15.2.2. Liver
15.2.3. Brain
15.2.4. Lymph Nodes
15.2.5. Others
15.3. Middle East and Africa Metastatic Colorectal
Cancer Market Revenue (US$ Mn) and Forecasts, By Treatment Type
15.3.1. Surgery
15.3.2. Radiation Therapy
15.3.3. Chemo Therapy
15.3.4. Targeted Therapy and Immunotherapy
15.3.5. Image Guided Therapy
15.3.6. Others
15.4. Middle East and Africa Metastatic Colorectal
Cancer Market Revenue (US$ Mn) and Forecasts, By Application
15.4.1. Kids
15.4.2. Adults
15.5. Middle East and Africa Metastatic Colorectal
Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.1. Healthcare Facilities
15.5.2. Specialized Cancer Centers
15.5.3. Research Centers
15.5.4. Others
15.6. Middle East and Africa Metastatic Colorectal
Cancer Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
15.6.1.1.1.
Lungs
15.6.1.1.2.
Liver
15.6.1.1.3.
Brain
15.6.1.1.4.
Lymph
Nodes
15.6.1.1.5.
Others
15.6.1.2.
Saudi
Arabia Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
15.6.1.2.1.
Surgery
15.6.1.2.2.
Radiation
Therapy
15.6.1.2.3.
Chemo
Therapy
15.6.1.2.4.
Targeted
Therapy and Immunotherapy
15.6.1.2.5.
Image
Guided Therapy
15.6.1.2.6.
Others
15.6.1.3.
Saudi
Arabia Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.1.3.1.
Kids
15.6.1.3.2.
Adults
15.6.1.4.
Saudi
Arabia Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
End-User
15.6.1.4.1.
Healthcare
Facilities
15.6.1.4.2.
Specialized
Cancer Centers
15.6.1.4.3.
Research
Centers
15.6.1.4.4.
Others
15.6.2. UAE
15.6.2.1.
UAE
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
15.6.2.1.1.
Lungs
15.6.2.1.2.
Liver
15.6.2.1.3.
Brain
15.6.2.1.4.
Lymph
Nodes
15.6.2.1.5.
Others
15.6.2.2.
UAE
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
15.6.2.2.1.
Surgery
15.6.2.2.2.
Radiation
Therapy
15.6.2.2.3.
Chemo
Therapy
15.6.2.2.4.
Targeted
Therapy and Immunotherapy
15.6.2.2.5.
Image
Guided Therapy
15.6.2.2.6.
Others
15.6.2.3.
UAE
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.2.3.1.
Kids
15.6.2.3.2.
Adults
15.6.2.4.
UAE Metastatic
Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
15.6.2.4.1.
Healthcare
Facilities
15.6.2.4.2.
Specialized
Cancer Centers
15.6.2.4.3.
Research
Centers
15.6.2.4.4.
Others
15.6.3. Egypt
15.6.3.1.
Egypt
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
15.6.3.1.1.
Lungs
15.6.3.1.2.
Liver
15.6.3.1.3.
Brain
15.6.3.1.4.
Lymph
Nodes
15.6.3.1.5.
Others
15.6.3.2.
Egypt
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
15.6.3.2.1.
Surgery
15.6.3.2.2.
Radiation
Therapy
15.6.3.2.3.
Chemo
Therapy
15.6.3.2.4.
Targeted
Therapy and Immunotherapy
15.6.3.2.5.
Image
Guided Therapy
15.6.3.2.6.
Others
15.6.3.3.
Egypt
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.3.3.1.
Kids
15.6.3.3.2.
Adults
15.6.3.4.
Egypt
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
15.6.3.4.1.
Healthcare
Facilities
15.6.3.4.2.
Specialized
Cancer Centers
15.6.3.4.3.
Research
Centers
15.6.3.4.4.
Others
15.6.4. Kuwait
15.6.4.1.
Kuwait Metastatic
Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By Metastasizing Site
15.6.4.1.1.
Lungs
15.6.4.1.2.
Liver
15.6.4.1.3.
Brain
15.6.4.1.4.
Lymph
Nodes
15.6.4.1.5.
Others
15.6.4.2.
Kuwait
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
15.6.4.2.1.
Surgery
15.6.4.2.2.
Radiation
Therapy
15.6.4.2.3.
Chemo
Therapy
15.6.4.2.4.
Targeted
Therapy and Immunotherapy
15.6.4.2.5.
Image
Guided Therapy
15.6.4.2.6.
Others
15.6.4.3.
Kuwait
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.4.3.1.
Kids
15.6.4.3.2.
Adults
15.6.4.4.
Kuwait
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
15.6.4.4.1.
Healthcare
Facilities
15.6.4.4.2.
Specialized
Cancer Centers
15.6.4.4.3.
Research
Centers
15.6.4.4.4.
Others
15.6.5. South Africa
15.6.5.1.
South
Africa Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
15.6.5.1.1.
Lungs
15.6.5.1.2.
Liver
15.6.5.1.3.
Brain
15.6.5.1.4.
Lymph
Nodes
15.6.5.1.5.
Others
15.6.5.2.
South
Africa Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
15.6.5.2.1.
Surgery
15.6.5.2.2.
Radiation
Therapy
15.6.5.2.3.
Chemo
Therapy
15.6.5.2.4.
Targeted
Therapy and Immunotherapy
15.6.5.2.5.
Image
Guided Therapy
15.6.5.2.6.
Others
15.6.5.3.
South
Africa Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.5.3.1.
Kids
15.6.5.3.2.
Adults
15.6.5.4.
South
Africa Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
End-User
15.6.5.4.1.
Healthcare
Facilities
15.6.5.4.2.
Specialized
Cancer Centers
15.6.5.4.3.
Research
Centers
15.6.5.4.4.
Others
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Metastatic Colorectal Cancer Market Revenue (US$ Mn)
and Forecasts, By Metastasizing Site
15.6.6.1.1.
Lungs
15.6.6.1.2.
Liver
15.6.6.1.3.
Brain
15.6.6.1.4.
Lymph
Nodes
15.6.6.1.5.
Others
15.6.6.2.
Rest of
Middle East & Africa Metastatic Colorectal Cancer Market Revenue (US$ Mn)
and Forecasts, By Treatment Type
15.6.6.2.1.
Surgery
15.6.6.2.2.
Radiation
Therapy
15.6.6.2.3.
Chemo
Therapy
15.6.6.2.4.
Targeted
Therapy and Immunotherapy
15.6.6.2.5.
Image
Guided Therapy
15.6.6.2.6.
Others
15.6.6.3.
Rest of
Middle East & Africa Metastatic Colorectal Cancer Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.6.3.1.
Kids
15.6.6.3.2.
Adults
15.6.6.4.
Rest of
Middle East & Africa Metastatic Colorectal Cancer Market Revenue (US$ Mn)
and Forecasts, By End-User
15.6.6.4.1.
Healthcare
Facilities
15.6.6.4.2.
Specialized
Cancer Centers
15.6.6.4.3.
Research
Centers
15.6.6.4.4.
Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Metastasizing Site
15.7.3. By Treatment Type
15.7.4. By Application
15.7.5. By End-User
16. Latin America Metastatic Colorectal Cancer
Market Analysis and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin America Metastatic Colorectal Cancer
Market Revenue (US$ Mn)
16.2. Latin America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Metastasizing Site
16.2.1. Lungs
16.2.2. Liver
16.2.3. Brain
16.2.4. Lymph Nodes
16.2.5. Others
16.3. Latin America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Treatment Type
16.3.1. Surgery
16.3.2. Radiation Therapy
16.3.3. Chemo Therapy
16.3.4. Targeted Therapy and Immunotherapy
16.3.5. Image Guided Therapy
16.3.6. Others
16.4. Latin America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Application
16.4.1. Kids
16.4.2. Adults
16.5. Latin America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By End-User
16.5.1. Healthcare Facilities
16.5.2. Specialized Cancer Centers
16.5.3. Research Centers
16.5.4. Others
16.6. Latin America Metastatic Colorectal Cancer
Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
16.6.1.1.1.
Lungs
16.6.1.1.2.
Liver
16.6.1.1.3.
Brain
16.6.1.1.4.
Lymph
Nodes
16.6.1.1.5.
Others
16.6.1.2.
Brazil
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
16.6.1.2.1.
Surgery
16.6.1.2.2.
Radiation
Therapy
16.6.1.2.3.
Chemo
Therapy
16.6.1.2.4.
Targeted
Therapy and Immunotherapy
16.6.1.2.5.
Image
Guided Therapy
16.6.1.2.6.
Others
16.6.1.3.
Brazil
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.1.3.1.
Kids
16.6.1.3.2.
Adults
16.6.1.4.
Brazil
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
16.6.1.4.1.
Healthcare
Facilities
16.6.1.4.2.
Specialized
Cancer Centers
16.6.1.4.3.
Research
Centers
16.6.1.4.4.
Others
16.6.2. Argentina
16.6.2.1.
Argentina
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Metastasizing Site
16.6.2.1.1.
Lungs
16.6.2.1.2.
Liver
16.6.2.1.3.
Brain
16.6.2.1.4.
Lymph
Nodes
16.6.2.1.5.
Others
16.6.2.2.
Argentina
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
16.6.2.2.1.
Surgery
16.6.2.2.2.
Radiation
Therapy
16.6.2.2.3.
Chemo
Therapy
16.6.2.2.4.
Targeted
Therapy and Immunotherapy
16.6.2.2.5.
Image
Guided Therapy
16.6.2.2.6.
Others
16.6.2.3.
Argentina
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.2.3.1.
Kids
16.6.2.3.2.
Adults
16.6.2.4.
Argentina
Metastatic Colorectal Cancer Market Revenue (US$ Mn) and Forecasts, By End-User
16.6.2.4.1.
Healthcare
Facilities
16.6.2.4.2.
Specialized
Cancer Centers
16.6.2.4.3.
Research
Centers
16.6.2.4.4.
Others
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By Metastasizing Site
16.6.3.1.1.
Lungs
16.6.3.1.2.
Liver
16.6.3.1.3.
Brain
16.6.3.1.4.
Lymph
Nodes
16.6.3.1.5.
Others
16.6.3.2.
Rest of
Latin America Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
16.6.3.2.1.
Surgery
16.6.3.2.2.
Radiation
Therapy
16.6.3.2.3.
Chemo
Therapy
16.6.3.2.4.
Targeted
Therapy and Immunotherapy
16.6.3.2.5.
Image
Guided Therapy
16.6.3.2.6.
Others
16.6.3.3.
Rest of
Latin America Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By Application
16.6.3.3.1.
Kids
16.6.3.3.2.
Adults
16.6.3.4.
Rest of
Latin America Metastatic Colorectal Cancer Market Revenue (US$ Mn) and
Forecasts, By End-User
16.6.3.4.1.
Healthcare
Facilities
16.6.3.4.2.
Specialized
Cancer Centers
16.6.3.4.3.
Research
Centers
16.6.3.4.4.
Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Metastasizing Site
16.7.3. By Treatment Type
16.7.4. By Application
16.7.5. By End-User
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2020
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. Amgen Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Arcus Biosciences, Inc.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Array BioPharma Inc
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. CARDIFF ONCOLOGY
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Celyad Oncology SA
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Chia Tai Tianqing Pharmaceutical Group Co.,
Ltd
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Elevar Therapeutics
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. F. Hoffmann-La Roche Ltd.
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. G1 Therapeutics, Inc.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Genentech USA, Inc.
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Immunovative Therapies, Ltd.
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Merck KGaA
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Mirati Therapeutics, Inc.
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Novartis AG
18.14.1. Company Details
18.14.2. Company Overview
18.14.3. Product Offerings
18.14.4. Key Developments
18.14.5. Financial Analysis
18.14.6. SWOT Analysis
18.14.7. Business Strategies
18.15. Scandion Oncology A/S
18.15.1. Company Details
18.15.2. Company Overview
18.15.3. Product Offerings
18.15.4. Key Developments
18.15.5. Financial Analysis
18.15.6. SWOT Analysis
18.15.7. Business Strategies
18.16. Shanghai Henlius Biotech, Inc.
18.16.1. Company Details
18.16.2. Company Overview
18.16.3. Product Offerings
18.16.4. Key Developments
18.16.5. Financial Analysis
18.16.6. SWOT Analysis
18.16.7. Business Strategies
18.17. Sumitomo Dainippon Pharma Co., Ltd.
18.17.1. Company Details
18.17.2. Company Overview
18.17.3. Product Offerings
18.17.4. Key Developments
18.17.5. Financial Analysis
18.17.6. SWOT Analysis
18.17.7. Business Strategies
18.18. Suzhou Zelgen Biopharmaceuticals Co., Ltd.
18.18.1. Company Details
18.18.2. Company Overview
18.18.3. Product Offerings
18.18.4. Key Developments
18.18.5. Financial Analysis
18.18.6. SWOT Analysis
18.18.7. Business Strategies
18.19. Symphogen
18.19.1. Company Details
18.19.2. Company Overview
18.19.3. Product Offerings
18.19.4. Key Developments
18.19.5. Financial Analysis
18.19.6. SWOT Analysis
18.19.7. Business Strategies
18.20. The Menarini Group
18.20.1. Company Details
18.20.2. Company Overview
18.20.3. Product Offerings
18.20.4. Key Developments
18.20.5. Financial Analysis
18.20.6. SWOT Analysis
18.20.7. Business Strategies
18.21. Treos Bio Limited
18.21.1. Company Details
18.21.2. Company Overview
18.21.3. Product Offerings
18.21.4. Key Developments
18.21.5. Financial Analysis
18.21.6. SWOT Analysis
18.21.7. Business Strategies
18.22. Other Market Participants
19. Key Findings
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.